For all TM combined, 28.5% (10,425) of patients received antineoplastic medication, most frequently those in which the TM CA15-3 for breast cancer was determined (4301, 53.0%) and least frequently the ones with Calcitonin for medullary thyroid cancer (153, 10.8%). This evidence concerns the gene CALCA and medullary thyroid gland carcinoma.